Factors causing dose variability in drug administration
- PMID: 2791189
- DOI: 10.1007/BF00257443
Factors causing dose variability in drug administration
Abstract
The variability of the drug dose actually given to cancer patients was analyzed. Three variability factors were quantitatively examined (body surface calculation, personalized dose calculation, and drug residuum in commercially available vials) and their variability was experimentally measured. A systematic reduction (mean, 7%; range, 2%-15%) and a random variability (4%-5%) of the dose given were demonstrated. These results draw attention to the role of some of the procedures of routine clinical activity in determining the amount of drug actually delivered. The analysis suggests that personalization of doses must be very accurate in both measurement and calculation and that the staff giving the drug needs to be carefully informed about the importance of drug residuum. The variability of the delivered dose can lead to the misclassification of patients in investigations on the dose-response relationship. This factor may be added to pitfalls previously reported to affect this type of retrospective analysis.
Similar articles
-
Body surface area capping may not improve cytotoxic drugs tolerance.Sci Rep. 2021 Jan 28;11(1):2431. doi: 10.1038/s41598-021-81792-6. Sci Rep. 2021. PMID: 33510207 Free PMC article.
-
Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan.Jpn J Clin Oncol. 2003 Jun;33(6):309-13. doi: 10.1093/jjco/hyg062. Jpn J Clin Oncol. 2003. PMID: 12913086
-
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.J Clin Oncol. 1996 Sep;14(9):2590-611. doi: 10.1200/JCO.1996.14.9.2590. J Clin Oncol. 1996. PMID: 8823340 Review.
-
[Use of body weight and body surface area in dosing of anticancer agents in adult patients].Bull Cancer. 2007 Jul;94(7):647-51. Bull Cancer. 2007. PMID: 17723945 French.
-
Dosing strategies for anticancer drugs: the good, the bad and body-surface area.Eur J Cancer. 2002 Sep;38(13):1677-84. doi: 10.1016/s0959-8049(02)00151-x. Eur J Cancer. 2002. PMID: 12175683 Review.